We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


LI-COR Near-Infrared Assays and Technology Offer Insight to Coronavirus Researchers

Credit: rawpixel

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "LI-COR Near-Infrared Assays and Technology Offer Insight to Coronavirus Researchers"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The SARS-CoV-2 coronavirus and subsequent COVID-19 pandemic places the subject of viruses and virology in the research spotlight for good reason. Scientists are seeking to understand the virus, characterize infectivity, and understand its mechanism of action in their quest to develop therapeutics and vaccines. Key to this process are quantifiable assays that provide robust data for all aspects of research.

LI-COR Biosciences has continued to support virology researchers with products, tools, and services to better understand SARS-CoV-2 and other viruses. Traditionally, infectivity of viruses that exhibit cytopathic effect (CPE) has been characterized using plaque assays. While effective, these methods can be tedious, time-consuming, and the results are subject to human error. Near-infrared (NIR) Western Blots and In-Cell Western™ Assays aim to provide a high-quality, reliable means to get answers to a variety of assays that are key to the study of viruses like SARS-CoV-2.

“Our In-Cell Western Assay combines the specificity of Western blotting with the replicability and throughput of an ELISA,” says Jeff Harford, LI-COR senior product marketing manager. “This results in the ability to quickly characterize a broad range of cell signaling parameters in the development of targeted therapeutics more efficiently. This includes viral titrations on both plaque forming and non-plaque forming viruses, and antiviral molecule screens.”

LI-COR is offering researchers a special Odyssey® CLx Viral Solution Package that is now available for priority delivery and at a reduced price. In addition to the Odyssey Imager, the package includes startup reagents, both basic and advanced virtual training from LI-COR scientists, and Empiria Studio® statistical analysis software.